A platform that aims to change outcomes for dogs diagnosed with cancer recently received $10 million in new funding that will allow the company to grow and give more dogs access to precision treatment.
FidoCure uses genetic testing to identify what genetic mutation might be behind a dog’s cancer. Once testing is complete, FidoCure offers precision medicine reports with recommendations for individualized, targeted therapy using the latest science available in both human and canine oncology. FidoCure is available nationwide through more than 200 participating veterinarians.
To learn more, visit fidocure.com.
